Prasugrel cuts risk of stent-related clots

The investigational antiplatelet drug prasugrel plus aspirin produced a marked and highly statistically significant reduction in the risk of coronary stent thrombosis (ST) - a major concern for physicians and patients with potentially fatal consequences - in patients who received a stent as compared to standard therapy with clopidogrel (Plavix) plus aspirin, according to a stent analysis from the head-to-head TRITON-TIMI 38 trial.

The findings were presented by Dr. Stephen Wiviott, an assistant professor of medicine at Harvard Medical School and investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, at the Society for Cardiovascular Angiography and Interventions Scientific Sessions with the American College of Cardiology's Innovation in Intervention: i2 Summit, in Chicago. In addition, the manuscript was simultaneously published online by the British medical journal, The Lancet.

In the TRITON-TIMI 38 trial, whose overall results were previously published, 12,844 of the 13,608 enrolled patients received at least one intracoronary stent. Of those patients, 6,461 received a bare metal stent (BMS), 5,743 patients received a drug-eluting stent (DES), and 640 patients received both BMS and DES at the time of enrollment. Stent thrombosis was a pre-defined secondary endpoint in the trial.

Prasugrel reduced the relative risk of coronary stent thrombosis (a new clot at the implanted stent site) over clopidogrel by 52 percent (1.13 percent vs. 2.35 percent, p30 days following the DES implantation (0.42 percent vs. 0.91 percent, p=0.04).

"The reduction in risk seen in patients in this analysis treated with prasugrel over patients treated with clopidogrel is encouraging for high-risk patients with acute coronary syndrome being managed with PCI," said J. Anthony Ware, M.D., Lilly vice president for cardiovascular/acute care.


(Editor compiled and published Prasugrel cuts risk of stent-related clots at HealthNewsTrack on March 29, 2008 sourced from Eli Lilly and Company - http://www.lilly.com/)

Heart disease - recent articles and current news stories:

- Sugar sweetened drinks may increase heart risk in women
- Financial reimbursement increases cardiac stress tests in patients
- Transcatheter aortic valve replacement TAVR shows superiority in heart patients
- Burmese python heart growth may benefit diseased human heart
- Expandable prosthesis resolves advanced aortic valve disease

Heart disease article/news source:

Read more health articles from Eli Lilly and Company and health articles from USA.

Heart disease - search related terms:

Angiography, Antiplatelet, Aspirin, Cardiology, Clopidogrel, Coronary stent thrombosis, Myocardial Infarction, Plavix, Prasugrel, Stent, Thrombolysis,
Heart disease books,

Searched keywords: prasugrel (13), stent (9), stent thrombosis (6),

Subscribe to Health News by Email

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
3.71